Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication

Authors: Choi, I. J.¹; Jung, H. C.¹; Choi, K. W.²; Kim, J. H.³; Ahn, D. S.⁴; Yang, U. S.⁵; Rew, J. S.⁶; Lee, S. I.⁷; Rhee, J. C.²; Chung, I. S.⁸; Chung, J. M.⁹; Hong, W.-S.¹⁰

Source: Alimentary Pharmacology & Therapeutics, Volume 16, Number 1, January 2002 , pp. 145-151(7)

Publisher: Blackwell Publishing

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Background:

Proton pump inhibitor-based triple therapies are recommended as the first-line treatment for Helicobacter pylori eradication. Aim:

To evaluate the efficacies of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy in a metronidazole resistance prevalent area and to compare the efficacies with standard triple therapy. Methods:

In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg). The three groups received each regimen twice daily for 7 days. Upper gastrointestinal endoscopy was performed before and 4 weeks after treatment. H. pylori status was determined by rapid urease test and ¹³C urea breath test. Results:

The eradication rates in the OAC250, OAC500 and OTC groups were 76.2%, 65.7% and 64.8% (95% confidence interval: 67.9-84.4%, 56.7-74.8% and 55.7-73.9%), respectively, by intention-to-treat analysis (P=0.149) and 92.8%, 87.2% and 84.1% (95% confidence interval: 84.4-97.3%, 77.9-93.8% and 73.9-91.2%), respectively, by per protocol analysis (P=0.088). All regimens were well tolerated and compliance was excellent. Conclusions:

Both low-dose clarithromycin triple therapy and tinidazole-containing triple therapy are effective and safe regimens for H. pylori eradication.

Document Type: Research article

DOI: 10.1046/j.1365-2036.2002.01130.x

Affiliations: 1: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea, 2: Department of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, South Korea, 3: Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea, 4: Department of Internal Medicine, Chonbuk National University College of Medicine, Chonju, South Korea, 5: Department of Internal Medicine, Pusan National University College of Medicine, Pusan, South Korea, 6: Department of Internal Medicine, Chonnam National University College of Medicine, Kwangju, South Korea, 7: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 8: Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 9: Department of Internal Medicine, Kyungpook National University College of Medicine, Taegu, South Korea, 10: Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, South Korea

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.